---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-039919"
form_type: "8-K"
ticker: null
cik: "0001008848"
company_name: "Acorda Therapeutics, Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T10:14:30.471377+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acorda receives Nasdaq extension until June 20, 2023 to meet $1 bid price rule

## Summary
- Nasdaq Hearings Panel grants extension to June 20, 2023 to regain compliance with $1 minimum bid price.
- To regain compliance, bid price must close at or above $1 for at least 10 consecutive trading days.
- If not achieved organically, company may effect a reverse stock split (1:2 to 1:20) authorized by shareholders in Nov 2022.
- CEO cites business plan focused on Inbrija growth, Ampyra maintenance, and fiscal discipline to drive organic compliance.

## SEC filing metadata
- accession: 0001193125-23-039919
- form_type: 8-K
- cik: 0001008848
- company_name: Acorda Therapeutics, Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1008848/000119312523039919/0001193125-23-039919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1008848/000119312523039919/d462809d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-039919
- JSON: https://secwatch.observer/filing/0001193125-23-039919.json
- Plain text: https://secwatch.observer/filing/0001193125-23-039919.txt

## Key facts
- Listing & Compliance Notices
  Acorda Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price.
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  source text: February 14, 2023, the Company received notice from Nasdaq granting the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until June 20, 2023. The Nasdaq Hearings Panel’s decision is subject to the Company’s continued compliance with applicable Nasdaq listing requirements and may be reviewed by the Nasdaq Listing and Hearing Review Council on its own within 45 days. The Company will actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the Minimum Bid Requirement, including
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008848/000119312523039919/0001193125-23-039919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.